ArticleFrontiers in oncology2026
Targeted therapy plus chemotherapy for advanced or metastatic triple-negative breast cancer: a PRISMA 2020 systematic review and meta-analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically review the efficacy of chemotherapy combined with targeted therapy in the handling of advanced triple-negative breast cancer (TNBC). Methods: A thorough literature search was carried out across several databases, including PubMed, EMBASE, ScienceDirect, and Chinese medical databases, for case-control trials on TNBC patients treated with chemotherapy combined with targeted therapy versus chemotherapy alone. Two separate researchers extracted the data, and the risk of bias was assessed using the Cochrane Manual 5.3. The meta-analysis was performed using RevMan 5.3. This review followed PRISMA 2020 and was registered in INPLASY (registration ID INPLASY202590085). Results: Following PRISMA guidelines, 2,136 records were identified, and five controlled studies involving 523 participants were included. Meta-analysis of progression-free survival (PFS) suggested a potential improvement in the targeted therapy plus chemotherapy group; however, the pooled result did not reach statistical significance (HR = 0.45, 95% CI 0.16-1.26; P = 0.13). Overall survival (OS) data were insufficient for quantitative meta-analysis, and the available controlled studies did not demonstrate a definitive survival benefit. The objective response rate (ORR) and disease control rate (DCR) were significantly higher with targeted therapy plus chemotherapy than with chemotherapy alone (P < 0.05). No significant increase in adverse events was observed. Conclusion: Targeted therapy plus chemotherapy improves tumor response outcomes in patients with advanced or metastatic TNBC without a clear increase in severe adverse events. However, evidence regarding PFS and OS benefits remains inconclusive because of limited studies, heterogeneity, and insufficient survival data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.